Associated Papers
Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age-Related Studies in Thai Adults and Cross-Population Comparisons.
Srimatimanon T et al.
Clinical and Translational Science, 2026
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
PharmVar GeneFocus: SLCO1B1.
Ramsey LB et al.
Clinical Pharmacology and Therapeutics, 2023
Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder.
Häkkinen K et al.
Molecular Pharmaceutics, 2023
PAnno: A pharmacogenomics annotation tool for clinical genomic testing.
Liu Y et al.
Frontiers in Pharmacology, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I et al.
European Journal of Clinical Pharmacology, 2022
The Effect of Single Nucleotide Variations in the Transmembrane Domain of OATP1B1 on in vitro Functionality.
Kiander W et al.
Pharmaceutical Research, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report.
Dagli-Hernandez C et al.
Annals of Translational Medicine, 2021
Rifampicin Transport by OATP1B1 Variants.
Litjens CHC et al.
Antimicrobial Agents and Chemotherapy, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.
Clarke JD et al.
Liver International : Official Journal of the International Association for the Study of the Liver, 2017
Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).
Lee HH et al.
British Journal of Clinical Pharmacology, 2017
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Caudle KE et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.
Grapci AD et al.
Balkan Journal of Medical Genetics : Bjmg, 2015
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE et al.
Pharmacogenetics and Genomics, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
Nelson D et al.
Antiviral Therapy, 2014
The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
Hua WJ et al.
Cardiovascular Therapeutics, 2012
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
de Graan AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
Ramsey LB et al.
Genome Research, 2012
Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs.
Nakanishi T et al.
Drug Metabolism and Pharmacokinetics, 2012
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
He J et al.
European Journal of Clinical Pharmacology, 2011
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M et al.
Pharmacological Reviews, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K et al.
Cancer Chemotherapy and Pharmacology, 2010
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R et al.
Pharmacogenetics and Genomics, 2010
Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.
Ide T et al.
Journal of Clinical Pharmacology, 2009
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
Seithel A et al.
Molecular Genetics and Genomics : Mgg, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
Maeda K et al.
Drug Metabolism and Pharmacokinetics, 2008
Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers.
Furihata T et al.
Pharmaceutical Research, 2007
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Kameyama Y et al.
Pharmacogenetics and Genomics, 2005
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Nishizato Y et al.
Clinical Pharmacology and Therapeutics, 2003
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0